Drug Trial Radar · NCT02207491
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Last checked: Nov 20, 2026Latest source record: Apr 13, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
411
Actual
Start
Jul 2014
Primary completion
Mar 2015
Study completion Mar 2015
Sponsor
- Lead sponsor
- Aerie PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 4, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%
Conditions
- Ocular Hypertension
- Open-angle Glaucoma
Interventions
Timolol maleate Ophthalmic Solution 0.5% BIDDrug
1 drop BID, AM/PM, OU
AR-13324 Ophthalmic Solution 0.02%Drug
1 drop once daily (QD), PM, OU
PlaceboOther
1 drop QD, AM, OU
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intraocular Pressure (IOP)Time frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aerie Pharmaceuticals
Bedminster, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.